Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlphaMedix in SSTR(+) NETs
NCT03466216Phase 1Terminated
- Sponsor
- Orano Med
- Start
- Feb 2018
- Primary completion
- Apr 2023
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Dotamtate Pb-212 in neuroendocrine tumors (NETs), sponsored by Orano Med. Primary endpoints: Dose-Limiting Toxicity and Adverse Events at 32 months. Started Feb 2018; status: terminated.
02
Drugs
Dotamtate Pb-212
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03466216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466216.